Oral Larazotide: Tight Junction Support for Leaky Gut and Celiac Disease The larazotide peptide specifically targets intestinal tight junctions, helping to reduce gut permeability and preventing the leakage of toxins into the bloodstream
Expert Opin Investig Drugs 32(5):355359 Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
However, intense training and competition often come with a cost in the form of injuries and the need for recovery
Ln da ca bn s khe mnh, trng sng v lun duy tr c s ti tr
The SUSTAIN-6 and LEADER trials both documented reduced progression of albuminuria (protein in urine), a marker of kidney injury
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining increasing attention as first-line agents for the treatment of diabetes and obesity, and with their potential to improve the muscle mass and function, they provide new ideas for the treatment of sarcopenia
)
